SCCA/Starbucks Successful at Cascade Cycling Classic

This past week the SCCA/Starbucks Cycling team sent a pro category ranked team of six women to Bend, Oregon to participate in the Cascade Cycling Classic.  The Cascade Cycling Classic is the longest consecutively run elite road bicycle race in the USA and is a regular fixture for most of North America’s top cyclists and teams and provides a venue for our amateur women’s squad to measure their performance against top professional cyclists.  The race consists of a prologue and 5 stages, with a total distance of approximately 240 miles and over 10,000 feet of elevation climb.

This proved to be a very successful campaign and the team finished with 5 of 6 racers still within the time cut.  The team ranked as high as 5th in general classification against top professionals with several racers finishing high up in individual stages.  Stages 1 & 3 were road stages with mountain top finishes at the Mount Bachelor ski resort.  In 90+ degree heat and elevations up to 5,700 feet, the physical effort to race is truly remarkable.  The other stages were either Time Trial, Criterium, and circuit races.  The team was also supported by a donation of a full time mechanic from Bikesport in Ballard.  Congrats to racers, pictured below left to right: Jen Burtner, Kat Reinhart, Cady Chintis, Sarah Carroll, Annalisa Fish, Vanessa Johnson.

scca-womens-team-600

While the pro women’s team was racing in Bend, the rest of the team was active at the Washington State Criterium Championships in Georgetown, securing one win and several podium spots across all men’s and women’s categories.

This weekend is the Marymoor Grand Prix at the Velodrome in Marymoor Park.  Come out and watch the best track racers on the west coast all day Friday and Saturday.  More information at www.velodrome.org.

Paul Camera is President of the SCCA/Starbucks Cycling Team. His day job is Director, Equipment and Packaging Development at Starbucks in Seattle.

    Posted in SCCA/Starbucks Cycling | Leave a comment

    Save the Date for a Swim

    swimacross-new-logoComing soon are two opportunities to swim for SCCA: Swim Across America’s Moses Lake Open Water Swim on August 23 and the Lake Washington Open Water Swim on September 6. Swim Across America, Inc. (SAA), is dedicated to raising money and awareness for cancer research, prevention, and treatment through swimming-related events. To date, Swim Across America has contributed over $1,000,000 for clinical research here at SCCA.

    So don’t get left out. Check out the Swim Across America website for more information about participating in this year’s events, including joining Team SCCA for the swim. And if you’re not a swimmer, then consider volunteering; SAA events typically need kayakers, boaters and lifeguards.  Also, if you register for the Lake Washington event before August 1, you’ll save $25 dollars on your registration.

    And more one thing: We’d like to thank BottleYourBrand, who over the past few years has played big part in SCCA’s Swim Across America. The first thing that greets a swimmer after churning two miles through the lake is a bottle of water from BottleYourBrand!

      Posted in Events | Leave a comment

      WE CAN in Africa

      we-can-logoThe Women’s Empowerment Cancer Advocacy Network (WE CAN) has just launched an Indiegogo campaign to help raise awareness about cancer screening, risk factors, and treatment of women in East Africa. WE CAN was founded by SCCA’s Dr. Julie Gralow in 2003. WE CAN’s mission is to raise awareness and change the face of breast and other women’s cancers in the developing world.

      This fall the group is putting on the 2nd annual East Africa WE CAN Advocacy, Education and Outreach Summit in Tanzania. In conjunction with the summit, WE CAN plans to produce and distribute for free a mini-documentary about the summit that features the stories of breast and cervical cancer survivors. Advocacy and awareness building are integral in helping to counter the growing cancer burden in developing nations, and WE CAN believes this video will be a powerful tool for raising awareness and saving lives. And that’s where the Conquering Cancer: Empowering African Sisters Indiegogo campaign comes in. As of today, the campaign has raised $2,000 with a goal of $25,000.

      Check out the video below to learn more about WE CAN and the upcoming summit in East Africa.

        Posted in General, Prevention | Leave a comment

        Rolling with SCCA/Starbucks

        After a highly successful spring season, the SCCA/Starbucks Cycling Team is now firmly entrenched in summer racing. While the spring consists mainly of longer road races, summer racing consists mainly of criterium races, weekly racing at the Marymoor Velodrome, and longer stage races.

        SCCA/Starbucks' Emily Alexander and Amanda Loser in control at last month’s Second Ascent Ballard Criterium.

        SCCA/Starbucks’ Emily Alexander and Amanda Loser in control at last month’s Second Ascent Ballard Criterium.

        Criterium races, or crits, are short-circuit courses, usually about 1.5 miles or less. Crits are spectator races, as the riders will ride the circuit within 5-10 minutes, so spectators can watch their favorite racers. The races are timed, with durations dependent upon the category of the race. Pro categories can race between 60-90 minutes. Because these are generally short flat races, the speeds are normally very fast, requiring great bike-handling skills.

        The other type of races that mark the end of the road racing season are stage races. Just like the Tour de France, these are multiple-day races with the top honors going to the lowest accumulated time. This week is the longest running national ranked stage race, the BMC Cascade Classic. Held in Bend, Oregon, this race attracts the top nationally ranked racers as well as some international riders not racing in the Tour de France. SCCA/Starbucks has a team of Category Pro 1/2 women competing against the professional teams. Look for a report next week on how they performed. Go SCCA/Starbucks!

        Paul Camera is President of the SCCA/Starbucks Cycling Team. His day job is Director, Equipment and Packaging Development at Starbucks in Seattle.

          Posted in SCCA/Starbucks Cycling | Leave a comment

          SCCA Clinical Trial Openings

          clinical-trialsListed below are clinical trials that have opened at SCCA in the last several weeks. These trials are looking at new treatments for patients with chronic myeloid leukemia, metastatic urothelial bladder cancer, colorectal cancer, HER2-positive breast cancer, and gastric or gastroesophageal junction adenocarcinoma. For more information about these trials, click on the links below. Check out our website to learn about the more than 200 ongoing clinical trials at SCCA. And follow us on Twitter at @SCCA_Trials for information about recently opened trials.

          Dasatinib Versus Imatinib for Chronic Phase Chronic Myeloid Leukemia
          An Open Label, Randomized (2:1) Phase IIb Study of Dasatinib Versus Imatinib in Patients With Chronic Phase Chronic Myeloid Leukemia Who Have Not Achieved an Optimal Response to 3 Months of Therapy With 400 mg Imatinib

          MPDL3280A for Locally Advanced or Metastatic Urothelial Bladder Cancer
          A Phase II, Multicenter, Single-Arm Study of MPDL3280A in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer

          MABp1 for Patients w/ Colorectal Cancer Who Are Losing Weight
          A Pivotal Phase III Study to Evaluate Overall Survival Using MABp1 as a Monotherapy in Metastatic Colorectal Cancer Patients With Cachexia

          Kadcyla + Pertuzumab vs. Herceptin + Pertuzumab + Taxane for HER2-positive Breast Cancer
          A Randomized, Multicenter, Open-Label, Phase III Trial Comparing Trastuzumab Plus Pertuzumab Plus A Taxane Following Anthracyclines Versus Trastuzumab Emtansine Plus Pertuzumab Following Anthracyclines As Adjuvant Therapy In Patients With Operable Her2 Positive Primary Breast Cancer

          Rilotumumab (AMG 102) with Epirubicin, Cisplatin, and Capecitabine (ECX) Gastric or Gastroesophageal Junction Adenocarcinoma (20121103)
          A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Rilotumumab (AMG 102) with Epirubicin, Cisplatin, and Capecitabine (ECX) as First-line Therapy in Advanced MET-Positive Gastric or Gastroesophageal Junction Adenocarcinoma

            Posted in Uncategorized | Leave a comment
            • This-One-Thing-260